Principal Investigator/Co-Principal Investigator
Joyce Liu MD/Ursula Matulonis MD
Assess the efficacy of either single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
Patients have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers. Patients with known deleterious germline BRCA1 or BRCA2 mutation on a clinical assay with an ovarian, primary peritoneal, or fallopian tube cancer of the following other Mullerian histologies are also eligible: clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma.
The target enrollment is 450 patients at approximately 180 over 2.5 years.
Activation: February 4, 2016
Protocol and Other Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website